Download Involvement of Honored Skippers

Wraparound Fundraising
May 2012
LLS is focused on cures
• While other large cancer organizations
target their mission investment on
prevention and early detection, LLS
invests in cures because most blood
cancers cannot be prevented or detected
early.
Research is the cancer answer
• LLS has been funding research for more
than 60 years and has a remarkable
record of supporting investigations that
lead to improved diagnostics and more
effective therapies.
• Today, LLS funds more blood cancer
research than any other voluntary health
agency in the U.S. or Canada.
Blood cancers are the #3
cancer killer in North America
• Only cancers of the respiratory and
digestive systems, including lung and
colon cancers, are more deadly.
Why does blood cancer research have
such a big impact?
• Studies of “liquid” versus “solid” cancers can be
easier and more productive, leading to
laboratory and clinical breakthroughs.
• Blood cancer research produced the first broadly
effective chemotherapies and the first successes
in molecularly targeted therapies.
• Almost half of the new cancer drugs approved in
the U.S. since 2000 (21/50) were approved to
treat one or more blood cancer, and LLS helped
advance most of them.
Blood cancer research is a gateway to
helping many patients
• As we learn more about different cancers,
we are finding similarities.
• This means that many drugs developed for
patients with a particular blood cancer can
help more patients, including patients with
other blood cancers, solid tumors and
serious non-malignant diseases.
• LLS research funding has played a vital role in many far-reaching
advances. For example: l The antibody drug Rituxan®, is approved
as a treatment for patients with forms of B-cell non-Hodgkin
lymphoma or chronic lymphocytic leukemia, and for patients with
rheumatoid arthritis. And it’s in late stage testing for patients with
other autoimmune diseases and to prevent rejection after organ
transplantation.
• The targeted drug, Gleevec®, is approved for patients with chronic
myelogenous leukemia, a form of acute lymphocytic leukemia and
rare forms of skin and stomach cancers. This drug and the newer
drugs, Sprycel® and Tasigna®, are showing promise for patients
with breast, prostate, lung and pancreatic cancer, melanoma and
other cancers.
• Another targeted drug, Revlimid®, is approved for patients with
myelodysplastic syndromes and for myeloma patients. It’s now in
clinical efficacy trials for lymphoma and leukemia patients and for
patients with bladder, brain, ovarian, prostate and other cancers.
LLS is driving innovative research
• Even with decades of LLS-supported progress, there are
still patients who urgently need more effective and safer
treatments. LLS is proactively funding academic
research in areas of unmet medical need and partnering
with companies to accelerate promising new therapies
through essential clinical trials.
• For example: l LLS actively solicits research proposals
focused on making today’s curative therapies safer,
identifying patients at risk of developing serious longterm side effects and developing strategies to prevent or
reduce the damage. With LLS support, a clinical trial in
Los Angeles is testing an approach to reduce bone
damage after anti-cancer steroid treatments.
• Through our Therapy Acceleration Program, LLS is partnered with
Acetylon Pharmaceuticals, Inc. to support early clinical testing of a
new drug for myeloma patients. This drug can reverse specific
abnormalities that can alter gene activities to cause a wide range of
cancers.
• Avila Therapeutics, Inc. was developing a new drug for rheumatoid
arthritis patients, but LLS knew that it might also help patients with
B-cell cancers. Thanks to LLS funding, this drug entered clinical
testing for these patients. Early findings are so positive that Celgene
Corporation recently acquired Avila to expand their pipeline of
promising oncology drugs.
• Also through Therapy Acceleration, LLS is advancing a new drug for
acute myeloid leukemia (AML) patients. This drug came out of grantfunded work in Toronto that showed an old anti-fungal drug could be
a powerful new anti-cancer treatment. The drug was reformulated
for oral use and is looking good in a clinical trial.
Wraparound Events
• Additional ways to raise funds
towards your Leukemia Cup
participation
• Funds raised count toward
incentives/Fantasy Sail qualifying
Examples of Wraparounds
•
•
•
•
•
Sailboat icon sales
Bake Sales
Garage Sales
Auctions
Ad Space on your boat
•
•
•
•
“Crew for Hire”
Ice Cream Social
Bowlathon
LLS Candy Bar
Sailboat Icons
Sailboat Icons Sales Outlets
•
•
•
•
Local businesses
Your Office
Restaurants/Bars near sailing venues
Marine/Sailing Supplies
– West Marine Caveat
• www.leukemiacup.org/ways/sailboaticons/
LLS Candy Bar
LLS Candy Bar
• Cost per box is $14.00 (this includes all local and state
tax)
• Shipping cost are not included in the $14.00
• Orders can be shipped to home or business locations
with UPS delivery in 7 to 10 days from the date of the
order
• Recommended selling price per bar is $2, which equates
to almost $60 in profit on a two-box order
• Almonds are non-allergenic and the chocolate is kosher
• Payment is made at the time of the order and the site
accepts MasterCard, Visa and American Express
• http://www.chocolateforacure.com/
Next Webcast
• June 4 – 3 pm Eastern – Gary Jobson
Google+ Hangout
• July 10 – 3 pm Eastern - Local Event
Sponsorships/Involving the entire sailing
community